This Phase 3 clinical trial was sponsored by Seqirus.
The purpose of this study was to evaluate the safety, immunogenicity, and lot-to-lot consistency of 3 lots of the Audenz vaccine for pandemic avian influenza, in approximately 2394 healthy adults and 797 healthy adults receiving placebo.
Enrollment was stratified by age: 18 to <65 years of age and ≥65 years of age, to allow adequate safety assessment of the entire age spectrum.
Results of this trial can be found here.